We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Preclinical safety and pharmacology of Hematide, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeys.
- Authors
Woodburn, Kathryn W; Schatz, Peter J; Fong, Kei-Lai; Wilson, Susan D; Ferrell, Thomas; Spainhour, Charles B; Norton, Daniel
- Abstract
The pharmacology, toxicokinetics, and safety of Hematide, a synthetic peptidic erythropoiesis-stimulating agent (ESA), were characterized. Hematide was given intravenously (0, 0.5, 5, and 50 mg/kg) weekly for five weeks with a 6- (rat) and 12-week (monkey) recovery period. The pharmacological action of Hematide resulted in polycythemia. Histopathology consistent with drug-induced exaggerated pharmacology was observed primarily in rats. Secondary sequelae resulting from pronounced polycythemia was considered the cause of deaths in rats and a single high-dose monkey. Toxicokinetic analysis indicated prolonged exposure. In conclusion, Hematide is a potent ESA and the safety and efficacy profile support clinical development.
- Publication
Drug and chemical toxicology, 2008, Vol 31, Issue 2, p229
- ISSN
0148-0545
- Publication type
Journal Article
- DOI
10.1080/01480540701873186